SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is facing intense scrutiny as investors weigh its massive $22B contracted backlog against concerns regarding heavy customer concentration, insider selling, and high-valuation execution risk. The community remains deeply divided, with bulls pointing to the company's long-term warehouse automation dominance and multi-year revenue visibility, while bears focus on recent equity offerings and the challenges of scaling hardware-heavy deployments.

Anthropic

Anthropic is currently trending as investors monitor its high-profile legal battle with federal agencies over military AI usage and the company's preparations for a highly anticipated IPO. Community discussion is heavily centered on the startup's multi-billion dollar compute deals, its rivalry with OpenAI, and the broader debate regarding the security implications of its advanced models.

OpenAI

OpenAI is trending as investors digest a strategic shift in capital expenditure and a potential IPO timeline as the company navigates intensifying competition from Anthropic and rising scrutiny over its massive infrastructure spending. The community remains highly polarized, with many debating the sustainability of current AI business models versus the long-term utility of the company's expanding agentic ecosystem.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community chatter as traders react to anticipation surrounding the upcoming Goliath mainnet launch. While some investors are accumulating in hopes of institutional adoption, others remain skeptical, citing historical price volatility and recurring cycles of skepticism within the community.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is drawing significant attention as community members anticipate a repeat of past parabolic moves, fueled by reports of extremely high borrow fees, scarce available shares for shorting, and a tightly held float. While some investors are bullish on a potential technical breakout above key resistance levels, others remain skeptical, citing ongoing concerns about the company's valuation, lack of revenue, and its involvement in active securities class-action litigation.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors weigh potential M&A speculation against a long-awaited court ruling on Medicare reimbursement for XPHOZAH. While management focuses on long-term IBSRELA growth and profitability, the community remains divided between those frustrated by share price stagnation and those accumulating shares, betting that current valuations overlook future growth and potential catalysts.

Themes ETF Trust - Leverage Shares 2X Long BBAI Daily ETF

Leverage Shares 2X Long BBAI Daily ETF

Investors are actively debating the merits of holding the 2X leveraged BAIG ETF versus the underlying BigBear.ai stock, with many community members focusing on volatility decay and the potential for magnified gains during market swings. The discussion is heavily polarized by varying strategies, ranging from long-term accumulation to aggressive short-term trading and speculation around future catalysts.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending as investors debate whether the stock represents a deep-value opportunity after its recent valuation pullback or a continued downtrend, with many in the community highlighting the company's strong brand loyalty and long-term growth story despite current macro headwinds. The discussion is heavily focused on potential catalysts like upcoming earnings, international expansion, and a rumored shift in sector rotation that could trigger a significant rebound.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is attracting intense investor attention as algorithmic market makers, institutional dark pools, and high-frequency trading behaviors dominate the order book, fueling community concerns that the platform now reflects a rigged system. Traders are actively debating whether these structural market forces, combined with speculative volatility and ongoing regulatory discussions, are suppressing fair price discovery for the broader tech sector.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

The healthcare sector is seeing significant inflows as investors rotate into defensive names, with the $XLV tracking toward all-time highs behind a surge in institutional accumulation. Community discussion is focused on the sector's relative strength and its role as a stable hedge, particularly as major pharma names drive index performance while biotech continues to exhibit high-conviction breakout setups.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher

PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April

PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest...

PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of PDS Biotechnology in a research note on Wednesday...

Why Is PDS Biotechnology Stock Gaining Wednesday?

PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.read more...

PDSB Stock Hits 37-Week High — Here’s The Latest On Its Therapy To Treat Metastatic Colorectal Cancer

Equity

The biotech firm said its Phase 2 trial of PDS01ADC showed a strong objective response rate and a 24-month survival rate.

PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

PDS Biotechnology Corporation

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.8885
Prev Close	$0.894
Open	$0.90
Dividend Yield	0.00%
50-Day Moving Average	$1.10
Beta	2.13
Avg. Volume	1.08M
PE Ratio	-1.33

52-Week High	$1.55
52-Week Low	$0.5068
Market Capitalization	$49.59M
EPS (Annual)	-$0.7437
Price to Book	12.82
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PDSBPDS Biotechnology Corporation

Latest PDSB News